$NKTX News

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Needham Reiterates Buy on Nkarta, Maintains $11 Price Target

Nkarta (NASDAQ:NKTX) Q1 2026 Narrower Loss Beats Estimates as Autoimmune Trial Advances

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

Nkarta Q1 EPS $(0.37), Inline

NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program

Nkarta shares are trading higher after the company announced an agreement with the FDA on protocols for its Ntrust-1 and Ntrust-2 clinical trials.

Nkarta shares are trading higher after the company announced an agreement with the FDA on protocols for its Ntrust-1 and Ntrust-2 clinical trials.

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

Nkarta Reveals FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease; Option To Redose Patients Granted In Both Ntrust-1 And Ntrust-2 Studies; Rheumatoid Arthritis Cohort To Be Added To Ntrust-2

Nkarta to Participate in Needham Virtual Healthcare Conference

Mizuho Maintains Outperform on Nkarta, Lowers Price Target to $12

Needham Maintains Buy on Nkarta, Raises Price Target to $11

Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights

Nkarta Files Base Prospectus To Offer Up To $350M In Securities

Nkarta Q4 EPS $(0.37) Misses $(0.34) Estimate

Nkarta to Participate in March Investor Conferences

We Think Nkarta (NASDAQ:NKTX) Needs To Drive Business Growth Carefully

Nkarta to Participate in Evercore Healthcare Conference

Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason